Novo Nordisk and Hims & Hers Resolve Legal Dispute Over Weight-Loss Drugs

Novo Nordisk, the manufacturer of the weight-loss drug Wegovy, has reached an agreement with Hims & Hers Health to sell its obesity medications on the telehealth platform. This development concludes a legal dispute that escalated last month when Novo Nordisk filed a lawsuit against Hims & Hers for patent infringement. The partnership announcement is anticipated shortly, potentially as soon as Monday.

Benzinga

The conflict began when Hims & Hers launched a compounded version of Wegovy, priced at $49, which prompted Novo Nordisk to sue for patent violations, claiming that the ingredients used in Hims' product infringed on its intellectual property. This legal action followed a previous partnership between the two companies, which was terminated by Novo Nordisk due to Hims & Hers' continued promotion of the compounded drug. The U.S. Food and Drug Administration (FDA) had also indicated it would scrutinize Hims & Hers for its marketing practices.

Benzinga

Following the news of the impending partnership, shares of Hims & Hers surged by approximately 39% in after-hours trading, reflecting investor optimism about the collaboration. In contrast, Novo Nordisk's stock experienced a slight decline during regular trading but saw a modest increase in after-hours trading. The weight-loss drug market is currently under pressure due to supply shortages, and the FDA's increased scrutiny of copycat drugs may further impact competition in this sector.

Benzinga

A spokesperson for Novo Nordisk stated, “We are always in conversation with companies that can help improve patient access to FDA-approved medicines for people living with chronic diseases.” This sentiment underscores the company's commitment to collaboration in enhancing patient access to its products.

Benzinga

Despite the resolution of the dispute, some industry observers have raised concerns about the implications of such partnerships. Critics argue that the proliferation of compounded versions of approved drugs could undermine the integrity of the pharmaceutical market and patient safety. The FDA's involvement indicates a growing concern over the regulation of these alternative products.

Reuters

While the partnership marks a significant development, there are still uncertainties regarding the specific terms of the agreement and how it will affect the availability of Wegovy and its competitors. Additionally, the extent of the FDA's regulatory actions against Hims & Hers remains unclear.

Reuters

• “We are always in conversation with companies that can help improve patient access to FDA-approved medicines for people living with chronic diseases.” — Novo Nordisk Spokesperson

Benzinga

This partnership between Novo Nordisk and Hims & Hers represents a pivotal moment in the weight-loss drug market, potentially reshaping the landscape for both companies and their competitors.

Benzinga